RAPT RAPT Therapeutics, Inc.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

$32.62  +0.45 (1.40%)
As of 11/30/2021 15:59:56 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2019
Outstanding shares:  29,546,058
Average volume:  180,486
Market cap:   $920,655,167
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75382E109
ISIN:        US75382E1091
Sedol:      BK5T6R0

---

Valuation   (See tab for details)

---

PE ratio:   -14.85
PB ratio:   4.70
PS ratio:   211.21
Return on equity:   -25.41%
Net income %:   -1,176.59%